Portal hypertension may influence the registration of hypointensity of small hepatocellular carcinoma in the hepatobiliary phase in gadoxetic acid MR

1Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments. J Hepatol 2015; 62: S121-30. doi: 10.1016/j.jhep.2015.01.003Bosch J Groszmann RJ Shah VH Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments J Hepatol 2015 62 S121 30 10.1016/j.jhep.2015.01.003451983325920081Open DOISearch in Google Scholar

2de Franchis R, Baveno VI Faculty. Expanding consensus in portal hypertension. J Hepatol 2015; 63: 743-52. doi: 10.1016/j.jhep.2015.05.022de Franchis R Baveno VI Faculty Expanding consensus in portal hypertension J Hepatol 2015 63 743 52 10.1016/j.jhep.2015.05.02226047908Open DOISearch in Google Scholar

3Ripoll C, Groszmann RJ, Garcia-Tsao G, Bosch J, Grace N, Burroughs A, et al. Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis. J Hepatol 2009; 50: 923-8. doi: 10.1016/j.jhep.2009.01.014Ripoll C Groszmann RJ Garcia-Tsao G Bosch J Grace N Burroughs A et al Hepatic venous pressure gradient predicts development of hepatocellular carcinoma independently of severity of cirrhosis J Hepatol 2009 50 923 8 10.1016/j.jhep.2009.01.014372114619303163Open DOISearch in Google Scholar

4Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, García-Criado A, et al. BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system. The 2022 update. J Hepatol 2022; 76: 681-93. doi: 10.1016/J.JHEP.2021.11.018 Reig M Forner A Rimola J Ferrer-Fàbrega J Burrel M García-Criado A et al BCLC strategy for prognosis prediction and treatment recommendation Barcelona Clinic Liver Cancer (BCLC) staging system The 2022 update. J Hepatol 2022 76 681 93 10.1016/J.JHEP.2021.11.018Open DOISearch in Google Scholar

5Galle PR, Forner A, Llovet JM, Mazzaferro V, Piscaglia F, Raoul JL, et al. EASL Clinical Practice Guidelines: management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236. doi: 10.1016/j.jhep.2018.03.019Galle PR Forner A Llovet JM Mazzaferro V Piscaglia F Raoul JL et al EASL Clinical Practice Guidelines: management of hepatocellular carcinoma J Hepatol 2018 69 182 236 10.1016/j.jhep.2018.03.01929628281Open DOISearch in Google Scholar

6Van Beers BE, Pastor CM, Hussain HK. Primovist, Eovist: what to expect? J Hepatol 2012; 57: 421-9. doi: 10.1016/j.jhep.2012.01.031Van Beers BE Pastor CM Hussain HK Primovist, Eovist: what to expect? J Hepatol 2012 57 421 9 10.1016/j.jhep.2012.01.03122504332Open DOISearch in Google Scholar

7Kitao A, Zen Y, Matsui O, Gabata T, Kobayashi S, Koda W, et al. Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging – correlation with molecular transporters and histopathologic features. Radiology 2010; 256: 817-26. doi: 10.1148/radiol.10092214Kitao A Zen Y Matsui O Gabata T Kobayashi S Koda W et al Hepatocellular carcinoma: signal intensity at gadoxetic acid-enhanced MR Imaging – correlation with molecular transporters and histopathologic features Radiology 2010 256 817 26 10.1148/radiol.1009221420663969Open DOISearch in Google Scholar

8Choi JW, Lee JM, Kim SJ, Yoon JH, Baek JH, Han JK, et al. Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker. Radiology 2013; 267: 776-86. doi: 10.1148/radiol.13120775Choi JW Lee JM Kim SJ Yoon JH Baek JH Han JK et al Hepatocellular carcinoma: imaging patterns on gadoxetic acid-enhanced MR Images and their value as an imaging biomarker Radiology 2013 267 776 86 10.1148/radiol.1312077523401584Open DOISearch in Google Scholar

9Ricke J, Seidensticker M. Molecular imaging and liver function assessment by hepatobiliary MRI. J Hepatol 2016; 65: 1081-2. doi: 10.1016/j. jhep.2016.10.004Ricke J Seidensticker M Molecular imaging and liver function assessment by hepatobiliary MRI J Hepatol 2016 65 1081 2 10.1016/j.jhep.2016.10.00427729223Open DOISearch in Google Scholar

10Kukuk GM, Schaefer SG, Fimmers R, Hadizadeh DR, Ezziddin S, Spengler U, et al. Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests. Eur Radiol 2014; 24: 2482-90. doi: 10.1007/s00330-014-3291-xKukuk GM Schaefer SG Fimmers R Hadizadeh DR Ezziddin S Spengler U et al Hepatobiliary magnetic resonance imaging in patients with liver disease: correlation of liver enhancement with biochemical liver function tests Eur Radiol 2014 24 2482 90 10.1007/s00330-014-3291-x25030459Open DOISearch in Google Scholar

11Kobi M, Paroder V, Flusberg M, Rozenblit AMM, Chernyak V. Limitations of GD-EOB-DTPA-enhanced MRI: can clinical parameters predict suboptimal hepatobiliary phase? Clin Radiol 2017; 72: 55-62. doi: 10.1016/j. crad.2016.10.004Kobi M Paroder V Flusberg M Rozenblit AMM Chernyak V Limitations of GD-EOB-DTPA-enhanced MRI: can clinical parameters predict suboptimal hepatobiliary phase? Clin Radiol 2017 72 55 62 10.1016/j.crad.2016.10.00427842889Open DOISearch in Google Scholar

12Okada M, Murakami T, Kuwatsuru R, Nakamura Y, Isoda H, Goshima S, et al. Biochemical and clinical predictive approach and time point analysis of hepatobiliary phase liver enhancement on Gd-EOB-DTPA-enhanced MR images: a multicenter study. Radiology 2016; 281: 474-83. doi: 10.1148/ radiol.2016151061Okada M Murakami T Kuwatsuru R Nakamura Y Isoda H Goshima S et al Biochemical and clinical predictive approach and time point analysis of hepatobiliary phase liver enhancement on Gd-EOB-DTPA-enhanced MR images: a multicenter study Radiology 2016 281 474 83 10.1148/radiol.201615106127195437Open DOISearch in Google Scholar

13Zhang W, Wang X, Miao Y, Hu C, Zhao W. Liver function correlates with liver-to-portal vein contrast ratio during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MR at 3 Tesla. Abdom Radiol 2018; 43: 2262-9. doi: 10.1007/s00261-018-1462-yZhang W Wang X Miao Y Hu C Zhao W Liver function correlates with liver-to-portal vein contrast ratio during the hepatobiliary phase with Gd-EOB-DTPA-enhanced MR at 3 Tesla Abdom Radiol 2018 43 2262 9 10.1007/s00261-018-1462-y29476347Open DOISearch in Google Scholar

14Öcal O, Peynircioglu B, Loewe C, van Delden O, Vandecaveye V, Gebauer B, et al. Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial. Eur Radiol 2021; 32: 1320-9. doi: 10.1007/s00330-021-08218-9 Öcal O Peynircioglu B Loewe C van Delden O Vandecaveye V Gebauer B et al Correlation of liver enhancement in gadoxetic acid-enhanced MRI with liver functions: a multicenter-multivendor analysis of hepatocellular carcinoma patients from SORAMIC trial Eur Radiol 2021 32 1320 9 10.1007/s00330-021-08218-9879502634467453Open DOISearch in Google Scholar

15Liang M, Zhao J, Xie B, Li C, Yin X, Cheng L, et al. MR liver imaging with Gd-EOB-DTPA: The need for different delay times of the hepatobiliary phase in patients with different liver function. Eur J Radiol 2016; 85: 546-52. doi: 10.1016/j.ejrad.2015.12.015Liang M Zhao J Xie B Li C Yin X Cheng L et al MR liver imaging with Gd-EOB-DTPA: The need for different delay times of the hepatobiliary phase in patients with different liver function Eur J Radiol 2016 85 546 52 10.1016/j.ejrad.2015.12.01526860666Open DOISearch in Google Scholar

16Ippolito D, Famularo S, Giani A, Orsini EB, Pecorelli A, Pinotti E, et al. Estimating liver function in a large cirrhotic cohort: Signal intensity of gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI. Dig Liver Dis 2019; 51: 1438-45. doi: 10.1016/J.DLD.2019.04.009Ippolito D Famularo S Giani A Orsini EB Pecorelli A Pinotti E et al Estimating liver function in a large cirrhotic cohort: Signal intensity of gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid-enhanced MRI Dig Liver Dis 2019 51 1438 45 10.1016/J.DLD.2019.04.009Open DOISearch in Google Scholar

17Yoon JH, Choi JI, Jeong YY, Schenk A, Chen L, Laue H, et al. Pre-treatment estimation of future remnant liver function using gadoxetic acid MRI in patients with HCC. J Hepatol 2016; 65: 1155-62. doi: 10.1016/j.jhep.2016.07.024Yoon JH Choi JI Jeong YY Schenk A Chen L Laue H et al Pre-treatment estimation of future remnant liver function using gadoxetic acid MRI in patients with HCC J Hepatol 2016 65 1155 62 10.1016/j.jhep.2016.07.02427476767Open DOISearch in Google Scholar

18Yoon JH, Lee JM, Kang H, Ahn SJ, Yang H, Kim E, et al. Quantitative assessment of liver function by using Gadoxetic Acid-enhanced MRI: hepatocyte uptake ratio. Radiology 2019; 290: 125-33. doi: 10.1148/radiol.2018180753Yoon JH Lee JM Kang H Ahn SJ Yang H Kim E et al Quantitative assessment of liver function by using Gadoxetic Acid-enhanced MRI: hepatocyte uptake ratio Radiology 2019 290 125 33 10.1148/radiol.201818075330375932Open DOISearch in Google Scholar

19Yamada S, Shimada M, Morine Y, Imura S, Ikemoto T, Saito Y, et al. A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging. PLoS One 2019; 14: e0210579. doi: 10.1371/journal.pone.0210579Yamada S Shimada M Morine Y Imura S Ikemoto T Saito Y et al A new formula to calculate the resection limit in hepatectomy based on Gd-EOB-DTPA-enhanced magnetic resonance imaging PLoS One 2019 14 e0210579 10.1371/journal.pone.0210579634714730682046Open DOISearch in Google Scholar

20Notake T, Shimizu A, Kubota K, Ikehara T, Hayashi H, Yasukawa K, et al. Hepatocellular uptake index obtained with gadoxetate disodium-enhanced magnetic resonance imaging in the assessment future liver remnant function after major hepatectomy for biliary malignancy. BJS Open 2021; 55(4): zraa048. doi: 10.1093/BJSOPEN/ZRAA048Notake T Shimizu A Kubota K Ikehara T Hayashi H Yasukawa K et al Hepatocellular uptake index obtained with gadoxetate disodium-enhanced magnetic resonance imaging in the assessment future liver remnant function after major hepatectomy for biliary malignancy BJS Open 2021 554 zraa048 10.1093/BJSOPEN/ZRAA048Open DOISearch in Google Scholar

21Daire JL, Leporq B, Vilgrain V, Van Beers BE, Schmidt S, Pastor CM. Liver perfusion modifies Gd-DTPA and Gd-BOPTA hepatocyte concentrations through transfer clearances across sinusoidal membranes. Eur J Drug Metab Pharmacokinet 2017; 42: 657-67. doi: 10.1007/s13318-016-0382-xDaire JL Leporq B Vilgrain V Van Beers BE Schmidt S Pastor CM Liver perfusion modifies Gd-DTPA and Gd-BOPTA hepatocyte concentrations through transfer clearances across sinusoidal membranes Eur J Drug Metab Pharmacokinet 2017 42 657 67 10.1007/s13318-016-0382-x27778300Open DOISearch in Google Scholar

22Ayuso C, Forner A, Darnell A, Rimola J, García-Criado Á, Bianchi L, et al. Prospective evaluation of gadoxetic-acid MR for the diagnosis of HCC in newly detected nodules ≤ 2 cm in cirrhosis. Liver Int 2019; 39: 1281-91. doi: 10.1111/liv.14133Ayuso C Forner A Darnell A Rimola J García-Criado Á Bianchi L et al Prospective evaluation of gadoxetic-acid MR for the diagnosis of HCC in newly detected nodules ≤ 2 cm in cirrhosis Liver Int 2019 39 1281 91 10.1111/liv.1413331077539Open DOISearch in Google Scholar

23Llop E, Berzigotti A, Reig M, Erice E, Reverter E, Seijo S, et al. Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors. J Hepatol 2012; 56: 103-8. doi: S0168-8278(11)00606-4 [pii] 10.1016/j.jhep.2011.06.027Llop E Berzigotti A Reig M Erice E Reverter E Seijo S et al Assessment of portal hypertension by transient elastography in patients with compensated cirrhosis and potentially resectable liver tumors J Hepatol 2012 56 103 8 S0168-8278(11)00606-4[pii]10.1016/j.jhep.2011.06.027Open DOISearch in Google Scholar

24Neri E, Bali MA, Ba-Ssalamah A, Boraschi P, Brancatelli G, Alves FC, et al. ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents. Eur Radiol 2016; 26: 921-31. doi: 10.1007/ s00330-015-3900-3Neri E Bali MA Ba-Ssalamah A Boraschi P Brancatelli G Alves FC et al ESGAR consensus statement on liver MR imaging and clinical use of liver-specific contrast agents Eur Radiol 2016 26 921 31 10.1007/s00330-015-3900-3477814326194455Open DOISearch in Google Scholar

25Ba-Ssalamah A, Bastati N, Wibmer A, Fragner R, Hodge JC, Trauner M, et al. Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: where are we? J Magn Reson Imaging 2017; 45: 646-59. doi: 10.1002/jmri.25518Ba-Ssalamah A Bastati N Wibmer A Fragner R Hodge JC Trauner M et al Hepatic gadoxetic acid uptake as a measure of diffuse liver disease: where are we? J Magn Reson Imaging 2017 45 646 59 10.1002/jmri.2551827862590Open DOISearch in Google Scholar

26Motosugi U, Ichikawa T, Oguri M, Sano K, Sou H, Muhi A, et al. Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging 2011; 29: 1047-52. doi: 10.1016/j.mri.2011.05.007Motosugi U Ichikawa T Oguri M Sano K Sou H Muhi A et al Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index Magn Reson Imaging 2011 29 1047 52 10.1016/j.mri.2011.05.00721775085Open DOISearch in Google Scholar

27Watanabe H, Kanematsu M, Goshima S, Kondo H, Onozuka M, Moriyama N, et al. Staging hepatic fibrosis: comparison of Gadoxetate Disodium-enhanced and diffusion-weighted MR imaging – preliminary observations. Radiology 2011; 259: 142-50. doi: 10.1148/radiol.10100621Watanabe H Kanematsu M Goshima S Kondo H Onozuka M Moriyama N et al Staging hepatic fibrosis: comparison of Gadoxetate Disodium-enhanced and diffusion-weighted MR imaging – preliminary observations Radiology 2011 259 142 50 10.1148/radiol.1010062121248234Open DOISearch in Google Scholar

28Besa C, Lewis S, Pandharipande PV, Chhatwal J, Kamath A, Cooper N, et al. Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid. Abdom Radiol 2017; 42: 179-90. doi: 10.1007/s00261-016-0841-5Besa C Lewis S Pandharipande PV Chhatwal J Kamath A Cooper N et al Hepatocellular carcinoma detection: diagnostic performance of a simulated abbreviated MRI protocol combining diffusion-weighted and T1-weighted imaging at the delayed phase post gadoxetic acid Abdom Radiol 2017 42 179 90 10.1007/s00261-016-0841-527448609Open DOISearch in Google Scholar

29Vietti Violi N, Taouli B. Abbreviated MRI for HCC surveillance: is it ready for clinical use? Eur Radiol 2020; 30: 4147-9. doi: 10.1007/s00330-020-06904-8Vietti Violi N Taouli B Abbreviated MRI for HCC surveillance: is it ready for clinical use? Eur Radiol 2020 30 4147 9 10.1007/s00330-020-06904-832394280Open DOISearch in Google Scholar

30Canellas R, Rosenkrantz AB, Taouli B, Sala E, Saini S, Pedrosa I, et al. Abbreviated MRI protocols for the abdomen. Radiographics 2019; 39: 744-58. doi: 10.1148/rg.2019180123Canellas R Rosenkrantz AB Taouli B Sala E Saini S Pedrosa I et al Abbreviated MRI protocols for the abdomen Radiographics 2019 39 744 58 10.1148/rg.201918012330901285Open DOISearch in Google Scholar

31Koh DM, Ba-Ssalamah A, Brancatelli G, Fananapazir G, Fiel MI, Goshima S, et al. Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging. Eur Radiol 2021; 31: 5615-28. doi: 10.1007/S00330-020-07637-4Koh DM Ba-Ssalamah A Brancatelli G Fananapazir G Fiel MI Goshima S et al Consensus report from the 9th International Forum for Liver Magnetic Resonance Imaging: applications of gadoxetic acid-enhanced imaging Eur Radiol 2021 31 5615 28 10.1007/S00330-020-07637-4827079933523304Open DOISearch in Google Scholar

32Hanada K, Nakai K, Tanaka H, Suzuki F, Kumada H, Ohno Y, et al. Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development. Drug Metab Pharmacokinet 2012; 27: 301-6. doi: 10.2133/ dmpk.dmpk-11-rg-077Hanada K Nakai K Tanaka H Suzuki F Kumada H Ohno Y et al Effect of nuclear receptor downregulation on hepatic expression of cytochrome P450 and transporters in chronic hepatitis C in association with fibrosis development Drug Metab Pharmacokinet 2012 27 301 6 10.2133/dmpk.dmpk-11-rg-07722166890Open DOISearch in Google Scholar

33Thakkar N, Slizgi JR, Brouwer KLR. Effect of liver disease on hepatic transporter expression and function. J Pharm Sci 2017; 106: 2282-94. doi: 10.1016/j.xphs.2017.04.053Thakkar N Slizgi JR Brouwer KLR Effect of liver disease on hepatic transporter expression and function J Pharm Sci 2017 106 2282 94 10.1016/j.xphs.2017.04.053561451128465155Open DOISearch in Google Scholar

34Shin NY, Kim MJ, Lim JS, Park MS, Chung YE, Choi JY, et al. Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases. Eur Radiol 2012; 22: 864-71. doi: 10.1007/ s00330-011-2333-xShin NY Kim MJ Lim JS Park MS Chung YE Choi JY et al Accuracy of gadoxetic acid-enhanced magnetic resonance imaging for the diagnosis of sinusoidal obstruction syndrome in patients with chemotherapy-treated colorectal liver metastases Eur Radiol 2012 22 864 71 10.1007/s00330-011-2333-x22108766Open DOISearch in Google Scholar

35Yoneda N, Matsui O, Ikeno H, Inoue D, Yoshida K, Kitao A, et al. Correlation between Gd-EOB-DTPA-enhanced MR imaging findings and OATP1B3 expression in chemotherapy-associated sinusoidal obstruction syndrome. Abdom Imaging 2015; 40: 3099-103. doi: 10.1007/s00261-015-0503-zYoneda N Matsui O Ikeno H Inoue D Yoshida K Kitao A et al Correlation between Gd-EOB-DTPA-enhanced MR imaging findings and OATP1B3 expression in chemotherapy-associated sinusoidal obstruction syndrome Abdom Imaging 2015 40 3099 103 10.1007/s00261-015-0503-z26187715Open DOISearch in Google Scholar

36Asenbaum U, Ba-Ssalamah A, Mandorfer M, Nolz R, Furtner J, Reiberger T, et al. Effects of portal hypertension on Gadoxetic Acid-Enhanced liver magnetic resonance: diagnostic and prognostic implications. Invest Radiol 2017; 52: 462-9. doi: 10.1097/RLI.0000000000000366Asenbaum U Ba-Ssalamah A Mandorfer M Nolz R Furtner J Reiberger T et al Effects of portal hypertension on Gadoxetic Acid-Enhanced liver magnetic resonance: diagnostic and prognostic implications Invest Radiol 2017 52 462 9 10.1097/RLI.000000000000036628622247Open DOISearch in Google Scholar

37Hectors SJ, Bane O, Kennedy P, Cuevas J, Thung S, Fischman A, et al. Noninvasive diagnosis of portal hypertension using gadoxetate DCE-MRI of the liver and spleen. Eur Radiol 2021; 31: 4804-12. doi: 10.1007/s00330-020-07495-0Hectors SJ Bane O Kennedy P Cuevas J Thung S Fischman A et al Noninvasive diagnosis of portal hypertension using gadoxetate DCE-MRI of the liver and spleen Eur Radiol 2021 31 4804 12 10.1007/s00330-020-07495-033411050Open DOISearch in Google Scholar

38Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma. Part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014; 273: 30-50. doi: 1148/ radiol.14132362Choi JY Lee JM Sirlin CB CT and MR imaging diagnosis and staging of hepatocellular carcinoma Part II. Extracellular agents, hepatobiliary agents, and ancillary imaging features. Radiology 2014 273 30 50 1148/radiol.14132362Open DOISearch in Google Scholar

39Renzulli M, Golfieri R, Bologna Liver Oncology Group (BLOG). Proposal of a new diagnostic algorithm for hepatocellular carcinoma based on the Japanese guidelines but adapted to the Western world for patients under surveillance for chronic liver disease. J Gastroenterol Hepatol 2016; 31: 69-80. doi: 10.1111/jgh.13150Renzulli M Golfieri R Bologna Liver Oncology Group (BLOG) Proposal of a new diagnostic algorithm for hepatocellular carcinoma based on the Japanese guidelines but adapted to the Western world for patients under surveillance for chronic liver disease J Gastroenterol Hepatol 2016 31 69 80 10.1111/jgh.1315026312574Open DOISearch in Google Scholar

40Renzulli M, Biselli M, Brocchi S, Granito A, Vasuri F, Tovoli F, et al. New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm. Gut 2018; 67: 1674-82. doi: 10.1136/ gutjnl-2017-315384Renzulli M Biselli M Brocchi S Granito A Vasuri F Tovoli F et al New hallmark of hepatocellular carcinoma, early hepatocellular carcinoma and high-grade dysplastic nodules on Gd-EOB-DTPA MRI in patients with cirrhosis: a new diagnostic algorithm Gut 2018 67 1674 82 10.1136/gutjnl-2017-31538429437912Open DOISearch in Google Scholar

41Ding Y, Rao SX, Chen C, Li R, Zeng MS. Assessing liver function in patients with HBV-related HCC: a comparison of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging with DWI. Eur Radiol 2015; 25: 1392-8. doi: 10.1007/ s00330-014-3542-xDing Y Rao SX Chen C Li R Zeng MS Assessing liver function in patients with HBV-related HCC: a comparison of T1 mapping on Gd-EOB-DTPA-enhanced MR imaging with DWI Eur Radiol 2015 25 1392 8 10.1007/s00330-014-3542-x25523455Open DOISearch in Google Scholar

42Haimerl M, Verloh N, Zeman F, Fellner C, Müller-Wille R, Schreyer AG, et al. Assessment of clinical signs of liver cirrhosis using T1 mapping on Gd-EOB-DTPA-enhanced 3T MRI. PLoS One 2013; 8: e85658 doi: 10.1371/JOURNAL.PONE.0085658Haimerl M Verloh N Zeman F Fellner C Müller-Wille R Schreyer AG et al Assessment of clinical signs of liver cirrhosis using T1 mapping on Gd-EOB-DTPA-enhanced 3T MRI PLoS One 2013 8 e85658 10.1371/JOURNAL.PONE.0085658Open DOISearch in Google Scholar